We have previously shown that human red blood cells (hRBCs) are subject to robust rejection by macrophages in immunodeficient mice. In this study, we found that mouse serum induces hRBC adherence to murine phagocytic cells, including professional phagocytic macrophages and neutrophils and non-professional phagocytic endothelial cells. Complement was found to be responsible for mouse-serum-induced hRBC adherence to murine phagocytic cells. Although hRBC survival was not improved in NOD/SCID mice with complement depletion by cobra venom factor (CVF), CVF significantly prolonged hRBC survival in mice that were depleted of phagocytic macrophages by clodronate-liposomes. This combination treatment also synergistically improved hRBC reconstitution in human CD34 + cell-grafted mice, offering a valuable model to examine human erythropoiesis and RBC function. These data indicate that complement, which might be dispensable for hRBC rejection by macrophages, is critical in hRBC rejection by other types of murine phagocytic cells, such as neutrophils and endothelial cells.
INTRODUCTION
As one of the most plentiful cell types in body, the red blood cell (RBC) is indispensable in oxygen and carbon dioxide transport (Goodnough et al., 2000) . In adults, RBCs differentiate from a limited number of hematopoietic stem cells (HSCs) in bone marrow in a process called erythropoiesis, which is a complicated and tightly regulated program that comprises distinct erythroid progenitor stages (Palis, 2014) . Any genetic error in this process may lead to hematological diseases, such as b-thalassemia and hereditary spherocytosis (Da Costa et al., 2013) . The recent development of effective gene editing strategies, such as CRISPR/Cas9 technology (Suzuki et al., 2016) , has increased the potential of curing these hematological disorders through transplantation of patient HSCs with the genetic errors corrected (Rees et al., 2010; Sankaran and Weiss, 2015) . However, these studies have been hampered by the lack of a suitable animal model that permits in vivo assessment of human erythroid differentiation from adult HSCs or induced pluripotent stem cell (iPSC)-derived HSCs and RBC function (Sankaran and Weiss, 2015) .
Immunodeficient mice have been used widely for human HSC transplantation (Hu and Yang, 2012a) . Although human HSC engraftment leads to the differentiation of multiple lineages of human hematopoietic cells, human RBC (hRBC) reconstitution cannot be achieved in these mice following human HSC transplantation, primarily due to rejection by murine phagocytic cells (Hu et al., 2011; Hu and Yang, 2012b) . Although fully matured CD71 À CD235a + enucleated hRBCs can be detected in humanized mice after macrophage depletion by clodronateliposome injection, their levels are insufficient, limiting its value as an in vivo model for the study of human hematological disorders, malaria infection, and relevant therapeutic interventions (Hu et al., 2011) . The low levels of hRBCs in human HSC-grafted mice that have been depleted of macrophages imply that other macrophageindependent mechanisms are involved, necessitating optimization of humanized mice with stable and high levels of hRBC chimerism in blood (Rahmig et al., 2016; Rongvaux et al., 2013) . In this study, we found that mouse complement is critical in mediating the rejection of hRBCs in immunodeficient mice. We show that elimination of murine complement by cobra venom factor (CVF) nearly completely abrogated the adherence of hRBCs to murine phagocytic cells in vitro and that CVF significantly prolonged the survival of infused hRBCs in macrophage-depleted mice. Moreover, combining CVF with macrophage depletion increased hRBC reconstitution in human CD34 + cell-grafted mice, constituting a valuable pre-clinical model to examine the efficacy and safety of RBC differentiation from gene-edited human HSCs.
RESULTS
Mouse, but Not Human, Sera Promote the Adherence of Human RBCs to Murine Phagocytic Cells Because adherence to phagocytic cells is a significant event in the phagocytosis of target cells, we first assessed the potential of mouse sera to induce adherence of hRBCs to murine phagocytic cells. Human RBCs adhered to non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse peritoneal cells (PCs) in the presence of NOD/SCID mouse sera but not human sera or in serum-free medium (Figures 1A and S1; Movies S1 and S2). However, mouse sera did not induce mouse RBC adherence to mouse PCs ( Figure 1A ) or hRBC adherence to mouse non-phagocytic fibroblast cells ( Figure S2A (Dini et al., 1995; Graham et al., 2009; Yu et al., 2016) . Thus, we next measured hRBC adherence to CD31 + mouse ECs in the presence and absence of mouse sera. As shown in Figure 1C , NOD/SCID mouse sera also elicited significant hRBC adherence to mouse ECs. These data demonstrate the ability of mouse sera to induce hRBC adherence to murine phagocytic cells, including macrophages and neutrophils, and non-professional phagocytic ECs. The adherence of hRBCs to mouse neutrophils and ECs in the presence of mouse sera explains our previous observation that, despite a significant improvement in hRBC survival, the rejection of hRBCs in NSG mice cannot be prevented completely by treatment with macrophage-depleting clodronate-liposomes (Hu et al., 2011) .
Opsonization of Human RBCs by Mouse Complement
Causes Human RBC Adherence to Murine Phagocytic Cells To determine whether mouse-serum-induced adherence of hRBCs to murine phagocytic cells was due to its effect on hRBCs, mouse phagocytic cells, or both, we measured the impact of pretreatment of hRBCs or mouse PCs with mouse sera on their adherence. Cell adherence was not detected when hRBCs were cultured in serum-free medium with untreated or mouse-serum-treated PCs (Figure 2A ). In contrast, mouse-serum-treated hRBCs adhered significantly to untreated mouse PCs when cultured in serumfree medium, to a level comparable with the adherence between untreated hRBCs and untreated PCs that were cultured in mouse sera ( Figure 2A ). The data indicate that the adherence of hRBCs to mouse PCs or the recognition of hRBCs by murine phagocytic cells in the presence of mouse sera is induced by mouse-serum-induced opsonization of hRBCs. In support of this possibility, we observed that hRBC-pre-adsorbed mouse sera (i.e., mouse sera that had been incubated with a saturating amount of hRBCs) did not cause the adherence of hRBCs to mouse PCs ( Figure 2B ). Thus, opsonization of hRBCs by mouse serum opsonins is likely to be the major mechanism for mouseserum-induced adherence of hRBCs to mouse PCs.
To characterize the mouse serum opsonins that induce hRBC adherence to mouse PCs, we evaluated the potential of preheated (at 56 C for 30 min) mouse sera to induce hRBC adherence to mouse phagocytic cells in comparison with untreated mouse sera. Unlike in untreated mouse sera, hRBCs did not show significant adherence to mouse PCs or ECs when cultured in preheated mouse sera ( Figure 2C ). These data indicate that the mouse serum opsonins that promote adherence of hRBCs to mouse phagocytic cells are heat labile. Mice on the NOD background lack hemolytic complement C5 (Baxter and Cooke, 1993) , but produce opsonic complement components, such as C3b (Patel and Harrison, 2008) . Because complement proteins are heat labile (Hair et al., 2012; Lewis et al., 2008; Nauta et al., 2004; Patel and Harrison, 2008) , it is possible that complement is the major serum opsonin that induces hRBC adherence to mouse phagocytic cells. In support of this possibility, we found that mouse sera treated with CVF, a complementactivating component of cobra venom that activates and thus exhausts C3 and C5 (Gowda et al., 1994) , did not induce hRBC adherence to mouse PCs ( Figure 2D ). Further, sera prepared from CVF-treated NOD/SCID mice also failed to induce adherence of hRBCs to mouse PCs ( Figure 2D ). Consistent with these observations, the addition of mouse complement proteins induced hRBC adherence to mouse PCs dose dependently in cultures without mouse sera or with preheated NOD/SCID sera ( Figure 2E ).
CVF Treatment Prolongs the Survival of Human RBCs in Macrophage-Depleted Immunodeficient Mice
We examined the potential of complement depletion to inhibit hRBC rejection in NOD/SCID mice. Human RBC survival was not improved in NOD/SCID mice that were treated with CVF compared with PBS-injected controls (Figure 3A) , despite the fact that the sera from the former failed to induce hRBC adherence to murine phagocytic cells in vitro ( Figure 2D ). In contrast, the same dose of CVF significantly increased hRBC survival (by approximately 3-fold) in NOD/SCID mice that were depleted of macrophages by clodronate-liposome injection ( Figure 3B ). Further, multiple injections of CVF prolonged the survival of infused hRBCs (up to approximately 3 weeks) in macrophagedepleted NOD/SCID mice ( Figure 3C ).
CVF Significantly Improves Human RBC Reconstitution in Human HSC-Grafted Immunodeficient Mice with Macrophage Depletion NOD/SCID B2m mice received 1.5 Gy total body irradiation, followed by intravenous injection of human CD34 + cells. Flow cytometric analysis of blood cells at week 7 post-transplantation revealed significant reconstitution with human CD45 + cells (ranging from 6.81% to 48.9%
of peripheral blood mononuclear cells) but no detectable hRBCs ( Figure 4A ). At week 8 post-transplantation, these mice were treated with clodronate-liposomes, CVF, clodronate-liposomes and CVF, or PBS (as controls), and monitored for hRBC chimerism in blood. Consistent with the hRBC transfusion experiments (Figure 3 ), hRBCs were only detected in mice that were depleted of macrophages ( Figure 4B ). In these mice, hRBCs appeared by day 5 and continued to increase throughout the observation period of 16 days, and the levels of hRBC chimerism in mice that were treated with both clodronate-liposomes and CVF were approximately 2-fold higher than in those treated with clodronate-liposomes alone ( Figure 4B ). In contrast, hRBCs remained nearly undetectable in CVFtreated mice and PBS-injected controls ( Figure 4B ). We have previously shown that macrophage depletion by clodronate-liposomes results in a significant increase in mature erythroid (CD71 À CD235a + ) cells in bone marrow (Hu et al., 2011) . Compared with mice treated with clodronate-liposomes, a further increase in CD71 À CD235a + erythroid cells were detected in the bone marrow from mice treated with a combination of clodronate-liposomes and CVF ( Figures S3A and S3B) . These results suggest a synergistic effect of clodronate-liposomes and CVF on the inhibition of hRBC rejection in immunodeficient mice. (B) Adherence of hRBCs to mPCs in the presence of fresh mSera or mSera that were adsorbed with hRBCs (2.5 3 10 9 hRBCs for 100 mL mSera). Left, representative pictures; right, adherence ratios (mean ± SD, n = 3 independent experiments). (C) Adherence of hRBCs to mPCs (top panel) or mouse ECs (mECs; bottom panel) in the presence of fresh or heated mSera. Left, representative pictures; right, adherence ratios (mean ± SD, n = 3 independent experiments). (D) Adherence of hRBCs to mPCs in the presence of NOD/SCID mSera treated with PBS (mSera-PBS) or CVF (mSera-CVF [in vitro]), or mSera prepared from CVF-treated NOD/SCID mice (mSera-CVF [in vivo]). Left, representative pictures; right, adherence ratios (mean ± SD, n = 3 independent experiments). (E) Adherence between hRBCs and mPCs co-cultured in mSera-free medium or heated mSera with or without addition of mouse complement proteins. Left, representative pictures; middle, adherence ratios in mSera-free medium or heated mSera with the indicated amounts of mouse complement proteins (n = 4 technical replicates); right, adherence ratios in heated mSera with addition of 3.6 mg mouse complement proteins (mean ± SD, n = 3 independent experiments). Scale bars represent 20 mm. *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant. Figure 3 . CVF Treatment Prolongs RBC Survival in Immunodeficient Mice with Macrophage Depletion (A) CFSE-labeled hRBCs were intravenously injected into NOD/SCID mice that were treated with PBS (n = 3 mice per group) or CVF (10 mg at day À1 and 5 mg at day 0; n = 5 mice per group). Blood was collected at the indicated times and analyzed for hRBC chimerism by flow cytometry. Representative flow cytometric profiles (left) and summarized data (right; mean ± SD) were shown. (B) Human (hRBCs) and NOD/SCID mouse (mRBCs) RBCs were labeled with high and low intensity of CFSE, respectively, mixed at approximately 1:1 ratio, and infused into NOD/SCID mice that were treated with PBS-liposomes (PBS; n = 3 mice per group) or clodronateliposomes (CLD, 100 mL at day À1, 50 mL at day 0; n = 3 mice per group) or clodronate-liposomes plus CVF (CLD + CVF; 100 mL CLD and 10 mg CVF at day À1; 50 mL CLD and 5 mg CVF at day 0; n = 4 mice per group). Blood was collected at the indicated times and the levels of surviving hRBCs and mRBCs were assessed by flow cytometry. Shown are representative staining profiles (left) and percentages of hRBCs (CFSE hi cells) in total CFSE + cells (mean ± SEM; right). (C) Human RBCs and NOD/SCID mRBCs were labeled with CFSE, mixed at approximately 1:1 ratio, and infused into NOD/SCID mice that received repeat treatment with clodronate-liposomes (CLD, 100 mL at day À1, 50 mL at day 0, and thereafter 30 mL every 3 days; n = 3 mice (legend continued on next page)
A B C

DISCUSSION
We have previously shown that hRBCs are rapidly rejected by recipient mouse macrophages in NOD/SCID and NSG mice (Hu et al., 2011; Hu and Yang, 2012b) . Because human CD47 cross-reacts with SIRPa of the NOD background mice (Takenaka et al., 2007) , the rejection of hRBCs by murine macrophages is not due to lacking of CD47-SIRPa signaling (Hu et al., 2011; Hu and Yang, 2012b) . The exact mechanisms of hRBC rejection by phagocytic cells in these immunodeficient mice remain unknown.
In this study, we found that hRBCs adhere to murine F4/ 80 + Ly6G À macrophages, F4/80 À Ly6G + neutrophils, and
ECs in the presence of mouse sera, indicating that both professional and non-professional phagocytic cells contribute to the clearance of hRBCs in mice. We also demonstrated that mouse complement is critical in serum-induced adherence of hRBCs to murine phagocytic cells, as the cell adherence was not observed in the presence of heated or CVFtreated mouse sera or sera from CVF-treated NOD/SCID mice. Although further studies are needed to identify the complement components that opsonize hRBCs to promote phagocytosis, the observed mouse C3 deposition on hRBCs incubated with fresh, but not heated or CVF-treated mouse sera ( Figure S4 ), and significant C3 depletion in CVFtreated sera ( Figure S3C ) suggest that C3 is involved. Immunodeficient mice on the NOD background lack hemolytic complement C5 (Baxter and Cooke, 1993) , suggesting that the activity of complement in facilitating hRBC rejection is mediated by its opsonic activity. However, although the ability of mouse sera to induce hRBC adherence to murine phagocytic cells is complement dependent, hRBC survival was not improved in CVFtreated NOD/SCID mice, indicating that the rejection of hRBCs in NOD/SCID mice may occur independently of complement. However, CVF significantly prolonged the survival of hRBCs in clodronate-liposome-treated mice. We have shown that depletion of murine macrophages by clodronate-liposomes significantly prolongs hRBC survival, but is insufficient in completely preventing the rejection of hRBCs in NSG mice (Hu et al., 2011) . Because injection of clodronate-liposomes efficiently depletes phagocytic macrophages, but not neutrophils or ECs (Van Rooijen and Sanders, 1994) , hRBC rejection in clodronate-liposome-treated mice might reflect the ability of neutrophils and ECs to reject hRBCs. Collectively, these observations raise the possibility that complement opsonization is important for hRBC rejection by neutrophils and ECs, but is not required for hRBC rejection by phagocytic macrophages.
Complement facilitates the rejection of xenogeneic cells that are coated with xenoantigen-specific antibodies (Yang and Sykes, 2007) . In this study, we found that mouse complement opsonizes hRBCs and promotes their rejection independently of antibodies. The fact that immunodeficient mice reject hRBCs but not human WBCs (Hu et al., 2011; Takenaka et al., 2007) suggests that the molecules recognized by mouse complement are likely expressed predominantly or specifically in hRBCs (Karnchanaphanurach et al., 2009; Marshall et al., 1996; Parker et al., 1984; Tambourgi et al., 2000) . Identification of the molecular targets of opsonization by mouse complement would help guide the development of better methods and mouse strains for the functional characterization of hRBCs in vivo.
Immunodeficient mice permit human HSC engraftment and differentiation and thus offer a valuable in vivo model for the study of human HSC function and hematopoiesis. However, it has been difficult to study human erythropoiesis or RBC function in human HSC-grafted mice. Although there are many explanations for the lack of hRBC reconstitution in human HSC-grafted mice, we have shown that robust rejection by recipient murine macrophages is sufficient to eliminate hRBCs in these mice, wherein hRBCs become detectable following the administration of clodronate-liposomes, despite their levels remaining low (Hu et al., 2011) . In this study, we show that CVF significantly improves hRBC reconstitution in HSCgrafted mice that have been depleted of macrophages by clodronate-liposomes. Thus, combination treatment with CVF and clodronate-liposomes is a simple but effective means of improving hRBC reconstitution in human HSCgrafted mice, which can be improved further by providing human cytokines that are essential for human erythropoiesis, such as interleukin-3 and erythropoietin (Chen et al., 2009; Hu et al., 2011) .
EXPERIMENTAL PROCEDURES
Animals and Human Tissues and Cells
NOD.CB17-Prkdcscid/J (NOD/SCID) mice and NOD.Cg-Prkdc scid B2mtm1Unc/JNju (NOD/SCID B2m) mice were purchased from Nanjing Biomedical Research Institute of Nanjing University. Animals were housed in a specific pathogen-free microisolator per group), or with clodronate-liposomes plus CVF (CLD + CVF; 100 mL CLD plus 10 mg CVF at day À1; 50 mL CLD plus 5 mg CVF at day 0, and thereafter 30 mL CLD plus 5 mg CVF every 3 days; n = 3 mice per group). The last injection of CLD (or CLD plus CVF) was given at day 15, and the control mice were injected with PBS-liposomes (PBS; n = 2 mice per group). Shown are representative staining profiles (left; gate CFSE + cells) and percentages of hRBCs (Ter119 -cells) in total CFSE + cells (mean ± SEM; right). *p < 0.05; n.s., not significant. environment and used in experiments at 5-8 weeks of age. Human blood was obtained from healthy volunteers, and human fetal liver tissues of gestational age of 17-20 weeks were obtained as discarded tissues from the First Hospital of Jilin University. Protocols involving the use of human tissues and animals were approved by the institutional review board and Institutional Animal Care and Use Committee of the First Hospital of Jilin University, and all of the experiments were performed in accordance with the protocols.
In Vitro RBC Adherence Assay
Mouse PCs collected from NOD/SCID mice 4 days after injection (i.p.) of 2% Bio-Gel polyacrylamide P100 (1 mL per mouse; BioRad) were used as effector cells (Hu et al., 2011) . In brief, 1 3 10 6 mouse PCs were cultured at 37 C for 1 hr to allow cells to attach to the plate, and human or mouse RBCs were added, and the cells were co-cultured in 150 mL RPMI 1640 medium or NOD/SCID mouse sera for 30 min. Unbounded RBCs were removed by washing six times with PBS, and cell adherence was observed under a microscope (Olympus IX51). The area of PCs attached to the plate (including PCs without or with RBC attached) were measured by Image-Pro plus software (Paton et al., 2011) , and the data are presented as adherence ratio that is calculated as: area of mouse PCs with RBC attached/area of all mouse PCs. In some experiments, magnetic-activated cell sorter ( + FLC injection, the mice were treated with PBS (n = 3 mice per group), CLD (5 injections; 1 injection every 3 days with 100 mL for the first injection and 25 mL thereafter; n = 5 mice per group), CVF (4 injections; 5 mg/injection every 4 days starting 1 day after CLD treatment; n = 3 mice per group), or both CVF and CLD (n = 5 mice per group). Shown are levels (%; mean ± SEM) of human RBCs in blood measured by flow cytometry at the indicated time points. *p < 0.05.
Macrophage Depletion in Mice
Macrophage depletion in vivo was performed by intravenous injection of liposome-encapsulated CL2MP (clodronate-liposomes, CLD). Clodronate was purchased from Sigma, and clodronate-liposome was prepared as described (Van Rooijen and Sanders, 1994) . Clodronate-liposomes were given at 100 and 50 mL per mouse at day 0 and day 1, and 30 mL per mouse, with an interval of 3 days for long-term studies. Control mice were treated on the same schedule with an equivalent volume of liposome-encapsulated PBS (PBS-liposome). The efficacy of macrophage depletion was confirmed by measuring the clearance of infused CD47 À/À mouse RBCs in randomly selected mice as described previously (Hu et al., 2011) .
Human RBC Clearance Assay
The hRBC clearance assay was performed as described previously (Hu et al., 2011) . In brief, human or mouse (as control) RBCs were labeled with CFSE, mixed and injected intravenously into NOD/SCID mice (1 3 10 8 RBCs per mouse) that were treated with PBS-liposomes or clodronate-liposomes (100 mL at day À1, with respect to RBC transfusion), or CVF (5 mg per mouse at day À1 and day 0 before RBC transfusion). To determine the kinetics of hRBC clearance, around 5 mL blood samples were collected into heparinized tubes at various time points after transfusion and stained with anti-human CD235a or Ter119 antibodies (BD Pharmingen), and the levels of surviving transfused RBCs were measured by flow cytometric analysis.
Human CD34 + Cell Transplantation in Immunodeficient Mice
NOD/SCID or NOD/SCID B2m mice were conditioned with 1.5 Gy total body irradiation and received human CD34 + fetal liver cells (FLCs; 1.5-5 3 10 5 /mouse, intravenously), as described previously (Jin et al., 2017; Lan et al., 2006) . CD34 + FLCs were isolated by a MACS separation system using anti-CD34 microbeads (Miltenyi Biotec). Levels of human hematopoietic cells were determined by flow cytometric analysis using various combinations of the following fluorescent-conjugated mAbs: anti-human CD45, CD19, CD235a; anti-mouse CD45 and Ter119; and isotype control mAbs (all purchased from BD Pharmingen). RBCs were collected from tail vein into the heparinized tube. Mononuclear cells were purified by density gradient centrifugation with Histopaque 1077 (Sigma-Aldrich). Analysis was performed on FACSCanto II or FACS Fortessa (BD Biosciences). Dead nucleated cells were excluded from the analysis by gating out lower forward scatter and high propidium iodide-retaining cells.
Statistical Analysis
The level of significant differences in group means was determined by the Student's t test. All statistical analysis was performed using Prism 5 (GraphPad software). A p value of %0.05 was considered significant in all analyses herein. 
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